lapatinib has been researched along with orlistat in 3 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (orlistat) | Trials (orlistat) | Recent Studies (post-2010) (orlistat) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 1,432 | 274 | 539 |
| Protein | Taxonomy | lapatinib (IC50) | orlistat (IC50) |
|---|---|---|---|
| Phosphatidylserine lipase ABHD16A | Homo sapiens (human) | 0.1 | |
| Pancreatic triacylglycerol lipase | Sus scrofa (pig) | 0.4214 | |
| Lipoprotein lipase | Homo sapiens (human) | 0.066 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.42 | |
| Hepatic triacylglycerol lipase | Homo sapiens (human) | 0.003 | |
| Pancreatic triacylglycerol lipase | Homo sapiens (human) | 0.3253 | |
| Translocator protein | Rattus norvegicus (Norway rat) | 1 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.42 | |
| Kappa-type opioid receptor | Mus musculus (house mouse) | 0.1903 | |
| Fatty acid synthase | Homo sapiens (human) | 2.99 | |
| Fatty-acid amide hydrolase 1 | Rattus norvegicus (Norway rat) | 0.01 | |
| Platelet-activating factor acetylhydrolase | Homo sapiens (human) | 0.05 | |
| Diacylglycerol lipase-alpha | Mus musculus (house mouse) | 0.02 | |
| Lysophosphatidylserine lipase ABHD12 | Homo sapiens (human) | 0.1682 | |
| Diacylglycerol lipase-beta | Homo sapiens (human) | 0.24 | |
| Monoacylglycerol lipase ABHD6 | Homo sapiens (human) | 0.03 | |
| Acyl-protein thioesterase 2 | Rattus norvegicus (Norway rat) | 0.17 | |
| Diacylglycerol lipase-alpha | Homo sapiens (human) | 0.2677 | |
| Endothelial lipase | Homo sapiens (human) | 0.006 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
1 review(s) available for lapatinib and orlistat
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for lapatinib and orlistat
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |